CanadaBis CapitalTSXV:CANB Return-on-Tangible-Equity is -6.64% as of Oct. 2025. The stock has 6 warning signs investors should review. Among 901 Drug Manufacturers companies, CanadaBis Capital ranks worse than 83.02% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. CanadaBis Capital's annualized net income for the quarter that ended in Oct. 2025 was C$-0.52 Mil. CanadaBis Capital's average shareholder tangible equity for the quarter that ended in Oct. 2025 was C$7.77 Mil. Therefore, CanadaBis Capital's annualized Return-on-Tangible-Equity for the quarter that ended in Oct. 2025 was -6.64%.
The historical rank and industry rank for CanadaBis Capital's Return-on-Tangible-Equity or its related term are showing as below:
TSXV:CANB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -567.83 Med: -35.71 Max: 90.78
Current: -15.71
During the past 10 years, CanadaBis Capital's highest Return-on-Tangible-Equity was 90.78%. The lowest was -567.83%. And the median was -35.71%.
TSXV:CANB's Return-on-Tangible-Equity is ranked worse than 83.02% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs TSXV:CANB: -15.71
CanadaBis Capital (TSXV:CANB) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
CanadaBis Capital Return-on-Tangible-Equity Related Terms
CanadaBis Capital Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for CanadaBis Capital's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs NPHC, BSPK, CPMD: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Oct. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -6.64% mean?
CanadaBis Capital (TSXV:CANB) has a Return-on-Tangible-Equity of -6.64% as of Oct. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CanadaBis Capital and its competitors. According to the industry distribution chart, CanadaBis Capital ranks #748 out of 901 companies in the Drug Manufacturers industry, placing it in the top 83%.
Is CanadaBis Capital's Return-on-Tangible-Equity too high?
CanadaBis Capital's current Return-on-Tangible-Equity is -6.64%. Based on the distribution chart, CanadaBis Capital ranks #748 out of 901 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does CanadaBis Capital's Return-on-Tangible-Equity compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #748 out of 901 companies for Return-on-Tangible-Equity. This places CanadaBis Capital in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CanadaBis Capital and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current Return-on-Tangible-Equity is -6.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current Return-on-Tangible-Equity of -6.64%. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current Return-on-Tangible-Equity is -6.64%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current Return-on-Tangible-Equity is -6.64% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 